ClinicalTrials.Veeva

Menu

Transition Study: Growth Hormone Therapy In Partial Growth Hormone Deficient Adolescents (TAUBER)

Pfizer logo

Pfizer

Status and phase

Completed
Phase 3

Conditions

Growth Hormone Deficiency

Treatments

Procedure: Radiography
Procedure: Blood sample

Study type

Interventional

Funder types

Industry

Identifiers

NCT00156143
A6281018
307-MET-9002-016

Details and patient eligibility

About

To evaluate in boys and girls the improvement in body composition under GH treatment in adolescents with CO-GHD who remain partially GHD after GH discontinuation.

Sex

All

Ages

15 to 20 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Males or females : Chronological age > or = 15 years and < or = 20 years for females
  • Chronological age > or = 17 years and < or = 20 years for males
  • GHD of childhood onset treated for at least 2 years
  • Last GH injection at least 12 months before baseline visit

Exclusion criteria

  • Turner's syndrome
  • Chronic hepatic impairment as shown by GGT and / or ASAT and / or ALAT > 2 X ULN

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
Ā© Copyright 2024 Veeva Systems